Clinical significance of serum thymus and activation-regulated chemokine in gastric cancer: potential as a serum biomarker.
Clinical significance of serum thymus and activation-regulated chemokine in gastric cancer: potential as a serum biomarker.
复制标题
DOI：
10.1111/cas.12505
复制
发表时间：
2014-10
期刊：
影响因子：
5.7
通讯作者：
Chung HW
中科院分区：
文献类型：
--
作者：
Lim JB;Kim DK;Chung HW
胸腺和活化调节趋化因子（TARC）可以刺激癌细胞的增殖和迁移。本研究探讨血清TARC在胃癌（GC）中的临床意义。在训练组（N = 25 /组）和独立验证数据集（90例正常、30例高风险、50例EGC和50例AGC）中，我们使用化学发光免疫分析法测定血清TARC、巨噬细胞来源的趋化因子、单核细胞趋化蛋白-1和干细胞因子（SCF）水平。采用单因素方差分析比较各组血清水平。为评价血清TARC对胃癌的诊断潜力，采用受试者工作特征曲线和logistic回归分析。采用Spearman相关分析血清TARC与胃癌临床病理特征的相关性。在训练数据集中，血清TARC与血清MDC、MCP-1和SCF相关。然而，只有癌症组血清TARC和SCF显著高于非癌症组（P < 0.001）。在验证数据集中，血清TARC也随着胃癌的发生而增加；AGC组（167.2±111.1 ng/mL）明显高于EGC组（109.1±67.7 ng/mL）、高危组（66.2±47.7 ng/mL）和正常组（67.5±36.2 ng/mL） （Bonferroni， P均< 0.001）。受试者工作特征曲线和逻辑回归显示，血清TARC作为单一标记物（敏感性72.0%，特异性71.1%，临界值0.37，逻辑回归）和多标记物组（敏感性72.6%，特异性88.2%，临界值0.54）具有显著的诊断潜力。Spearman相关分析显示，血清TARC与肿瘤大小（γs = 0.227, P = 0.028）、t期（γs = 0.340, P = 0.001）、n期（γs = 0.318, P = 0.002）、m期（γs = 0.346, P = 0.001）密切相关。血清TARC是一种很有前途的GC血清生物标志物。
Thymus and activation-regulated chemokine (TARC) can stimulate cancer cell proliferation and migration. The present study evaluated the clinical significance of serum TARC in gastric cancer (GC). We measured serum TARC, macrophage-derived chemokine, monocyte chemotactic protein-1 and stem cell factor (SCF) levels using a chemiluminescent immunoassay along the GC carcinogenesis (normal, high-risk, early GC [EGC] and advanced GC [AGC]) in both training (N = 25 per group) and independent validation datasets (90 normal, 30 high-risk, 50 EGC and 50 AGC). Serum levels were compared among groups using one-way analysis of variance. To evaluate the diagnostic potential of serum TARC for GC, receiver operating characteristic curve and logistic regression analyses were performed. Correlations between serum TARC and GC clinicopathological features were analyzed using Spearman's correlation. In the training dataset, serum TARC correlated with serum MDC, MCP-1 and SCF. However, only serum TARC and SCF were significantly higher in cancer groups than non-cancer groups (P < 0.001). In the validation dataset, serum TARC also increased along the GC carcinogenesis; the AGC group (167.2 ± 111.1 ng/mL) had significantly higher levels than the EGC (109.1 ± 67.7 ng/mL), the high-risk (66.2 ± 47.7 ng/mL) and the normal (67.5 ± 36.2 ng/mL) groups (Bonferroni, all P < 0.001). Receiver operating characteristic curves and logistic regression demonstrated the remarkable diagnostic potential of serum TARC as a single marker (72.0% sensitivity and 71.1% specificity; cutoff point, 0.37; logistic regression) and in a multiple-marker panel (72.6% sensitivity and 88.2% specificity; cutoff point, 0.54). Spearman's correlation showed that serum TARC was closely correlated with tumor size (γs = 0.227, P = 0.028), T-stage (γs = 0.340, P = 0.001), N-stage (γs = 0.318, P = 0.002) and M-stage (γs = 0.346, P = 0.001). Serum TARC is a promising serum biomarker for GC.
登录
查看更多内容
影响因子：
11.2
作者：
Olkhanud PB;Baatar D;Bodogai M;Hakim F;Gress R;Anderson RL;Deng J;Xu M;Briest S;Biragyn A
通讯作者：
Biragyn A
影响因子：
2.4
作者：
He CZ;Zhang KH;Li Q;Liu XH;Hong Y;Lv NH
通讯作者：
Lv NH
影响因子：
9.3
作者：
Bossuyt, PM;Reitsma, JB;de Vet, HCW
通讯作者：
de Vet, HCW
影响因子：
2.9
作者：
Chung, Hye Won;Kim, Ju Won;Lim, Jong-Baeck
通讯作者：
Lim, Jong-Baeck
影响因子：
2.8
作者：
Al-haidari, Amr A.;Syk, Ingvar;Thorlacius, Henrik
通讯作者：
Thorlacius, Henrik